Lilly Statement on Novel Coronavirus and the Reliable Supply of the Company's Medicines
Mar 03, 2020, 07:00 ET
INDIANAPOLIS, March 3, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) issued the following statement today regarding the novel coronavirus:
Among the concerns raised due to the impact of the novel coronavirus is whether patients can count on a reliable supply of medicine. Lilly does not anticipate shortages for any of our products, including all forms of insulin.
Since the initial outbreak, Lilly has been closely monitoring our supply chain for potential impact to the supply of our medicines around the world. Lilly does not source active pharmaceutical ingredients (API) for any of our approved medicines from China, and our insulin manufacturing sites in the United States and Europe have not been impacted by coronavirus. Lilly insulin and other medicines are available, as normal, in U.S. pharmacies. Pharmacies that don't have certain medicines in stock can order them from wholesalers, with delivery in 1-2 days.
Globally, our manufacturing network is fully operational and taking steps to prevent impact. We're also in close communication with key suppliers to ensure appropriate supplies of raw materials. As the global situation evolves, we will continue to take the steps necessary to safeguard the reliable supply of our medicines.
About Eli Lilly and Company
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. C-LLY
This release contains forward-looking statements regarding the supply of Lilly medicines. These statements are based on management's current expectations, but actual results may differ materially. Other risk factors that may affect the company's results can be found in the company's latest Forms 10-K and 10-Q filed with the U.S. Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
Refer to: |
Scott MacGregor; [email protected]; +1 317-440-4699 (Media) |
Kevin Hern; [email protected]; +1 317-277-1838 (Investors) |
SOURCE Eli Lilly and Company
Share this article